Drug Trial Radar · NCT00904280
Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy
Last checked: Nov 20, 2026Latest source record: May 19, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
239
Actual
Start
Mar 2001
Primary completion
Jul 2003
Study completion Jul 2003
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- May 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and tolerability of oxymorphone ER as an analgesic in cancer and lower back pain subjects having chronic moderate to severe pain.
Conditions
- Cancers, Pain
- Lower Back Pain
Interventions
Oxymorphone ERDrug
Open label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monthly assessments of pain with the Brief Pain Inventory (BPI) questionnaire, recall of average pain relief, total rescue medication usage and subject's and physician's global assessment of oxymorphone ERTime frame: 1 year study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Arizona Clinical Research Center
Tucson, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.